Retatrutide pharmacokinetics: what is the half-life?

What is retatrutide's half-life?

In a Phase 1 study of 45 healthy adults in Singapore, retatrutide's group-average half-lives spanned 134 to 165 hours, about 5.6 to 6.9 days, a result for that small, mostly male group only (Coskun et al., Cell Metabolism, 2022). A half-life is the time for the amount in the blood to fall by half. A Phase 1b study of 72 adults with type 2 diabetes reports a half-life of approximately six days, in an early-phase study funded by the developer (Urva et al., The Lancet, 2022). The retatrutide research guide covers what the compound is; this page covers what the body does to it.

A half-life is a clock, not a wall. After one half-life, about half of the measured amount remains in circulation; after two, about a quarter. In the Phase 1b study of 72 adults with type 2 diabetes, a half-life near six days meant the measured concentration fell by half roughly once a week in that group, a small early-phase result that does not describe other people (Urva et al., The Lancet, 2022).

The summary hides real spread. In the small Phase 1 study of 45 healthy adults in Singapore, individual half-lives ran from 104 to 225 hours, the minimum and maximum in the trial's t½ column, a wider span than the 134-to-165-hour band of group means, so in that small study one person's value could sit well away from a group figure (Coskun et al., Cell Metabolism, 2022).

Evidence limits

What has not been published about retatrutide's pharmacokinetics?

The Coskun 2022, Urva 2022 and Carneiro 2026 papers checked on 14 October 2026 contain no Phase 3 pharmacokinetic tables. They report no head-to-head pharmacokinetic comparison of retatrutide against semaglutide or tirzepatide — how retatrutide, Mounjaro, and Ozempic differ is a comparison of separate published records, not of one shared measurement. This page reports no accumulation ratio or time-to-steady-state figure because the full pharmacokinetic table in Urva et al. (The Lancet, 2022) could not be retrieved on 14 October 2026.

The people behind the numbers matter as much as the numbers. The Singapore study enrolled 45 healthy adults, of whom 42 were male and 44 were Asian, so its results may not describe women or other populations (Coskun et al., Cell Metabolism, 2022). And the weight and blood-sugar changes reported in these same papers are pharmacodynamic outcomes, what the compound did in the body, not pharmacokinetics.

What does pharmacokinetics actually measure?

Pharmacokinetics is the study of what the body does to a compound over time — how fast it arrives in the blood, how high it climbs, how widely it spreads, and how long it takes to leave. Four measured quantities carry most of the answer: Cmax, the highest concentration reached; Tmax, how long it took to get there; t½, the half-life; and AUC, total exposure, the area under the whole concentration-versus-time curve. Retatrutide's early clinical pharmacokinetic measurements discussed here come from two early-phase trials: NCT03841630, a single-exposure study in 45 healthy adults in Singapore (Coskun et al., Cell Metabolism, 2022), and NCT04143802, a repeated-exposure study in 72 adults with type 2 diabetes (Urva et al., The Lancet, 2022).

Pharmacokinetics has a mirror discipline, and the reader will meet the distinction again: pharmacokinetics is what the body does to the compound, while pharmacodynamics is what the compound does in the body. The gastric-emptying paper on retatrutide's record is the clean example: Urva et al. examined gastric emptying as a pharmacodynamic endpoint (Diabetes, Obesity and Metabolism, 2023).

The two Phase 1 trials behind the half-life, peak-timing and proportionality figures on this page ran from March to July 2019 in Singapore and from December 2019 to December 2020 in the United States — how long retatrutide has been studied lays out that full timeline, and where these two early studies sit inside it.

How long does retatrutide take to reach peak levels in the blood?

In the Phase 1 study of 45 healthy adults, the median time to peak blood concentration of retatrutide after a single exposure was 72 hours in the lowest group and 12 hours in the second-highest group, so group medians ran from 12 to 72 hours, with wide individual spreads at every level; the result describes that small study only (Coskun et al., Cell Metabolism, 2022).

The medians hide wide spreads. In the same Phase 1 study of 45 healthy adults, the lowest group's median time to peak was 72.0 hours with individuals out to 119.8 hours, and the second-highest group's earliest individual peak came at 4 hours against a median of 12.0, so in that small study a median does not describe any single participant (Coskun et al., Cell Metabolism, 2022). The table below lists what each study enrolled and measured.

How long does retatrutide take to kick in, according to studies?

In the Phase 1 study of 45 healthy adults, group-median time to peak blood concentration after a single exposure was 12 to 72 hours, a result from one small study that measures a blood peak, not the start of an effect (Coskun et al., Cell Metabolism, 2022). The Coskun 2022, Urva 2022 and Jastreboff 2023 papers checked on 14 October 2026 do not define a moment at which retatrutide starts to work. Their weight outcomes were reported over weeks, each set out below with its study.

In the Phase 1 study of 45 healthy adults, a body-weight reduction persisted up to day 43 after a single exposure, an early safety-study finding that does not describe other people (Coskun et al., Cell Metabolism, 2022). In the 12-week Phase 1b study of 72 adults with type 2 diabetes, the placebo-adjusted body-weight reduction reached up to 8.96 kg in the highest group, a result from one small early-phase study that does not describe other groups (Urva et al., The Lancet, 2022).

In the Phase 2 obesity trial of 338 adults, the highest arm averaged -17.5% at 24 weeks and -24.2% at 48 weeks, a result for that trial population from a trial funded by the developer (Jastreboff et al., New England Journal of Medicine, 2023). In an exit-interview study of 40 adults with obesity from the Phase 2 trial, funded by the developer, 31 of 36 retatrutide-treated participants said their eating habits had changed within the first 8 weeks; interviews rely on recall, so that figure is a signal about timing, not a measurement (Goetz et al., Obesity Pillars, 2025). The study findings page sets out those results with their limits.

How long does retatrutide last in the body?

In the 72-adult Phase 1b study in type 2 diabetes, retatrutide's half-life was approximately six days, so the measured amount fell by half about once a week in that group, a small early-phase result (Urva et al., The Lancet, 2022). In the Singapore study of 45 healthy adults individual half-lives ran from 104 to 225 hours, a small single-exposure result (Coskun et al., Cell Metabolism, 2022). No complete-clearance time was reported in the Coskun 2022, Urva 2022 and Carneiro 2026 papers checked for this page on 14 October 2026. In a 2026 analytical study of four adults who were using retatrutide outside a trial, intact retatrutide stayed detectable in plasma for approximately 56 days after the first exposure and none was found in urine, a detection result from four people and a method-validation design, not a clearance time (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026).

A half-life is a statistical clock, not an expiry date. The amount keeps falling through each half-life, and how long a trace shows up depends on the test. In the 2026 study of four adults who were using retatrutide outside a trial, the limit of detection was 6.14 ng/mL in plasma and the abstract does not name the product source, so the detection window belongs to that method and those samples (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026).

How long any effect lasts after treatment stops is a separate question from how long the molecule lasts. TRIUMPH-6 (NCT06859268) follows participants through an 80-week lead-in and then randomises them to continue retatrutide or switch to placebo, and it lists primary completion as estimated for April 2028 (ClinicalTrials.gov, checked 14 October 2026).

Does retatrutide exposure rise in step with the dose?

In the Phase 1 study of 45 healthy adults, retatrutide's pharmacokinetics appeared nearly dose-proportional across six ascending groups, meaning total exposure rose roughly in step with the amount given, in a small developer-funded study that does not establish proportionality outside the range it studied (Coskun et al., Cell Metabolism, 2022). The 72-adult Phase 1b study in type 2 diabetes reported dose-proportional pharmacokinetics as well, in a small early-phase trial funded by the developer that does not establish proportionality outside the groups it studied (Urva et al., The Lancet, 2022).

Predictable on average is not identical person to person. In the Phase 1 study of 45 healthy adults, coefficients of variation — the spread around the mean, expressed as a percentage — ran from 13% to 34% for total exposure and from 10% to 37% for peak concentration across the six groups, so in that small study the same group produced meaningfully different exposures in different people and a mean describes no single participant (Coskun et al., Cell Metabolism, 2022).

Why does retatrutide stay in the blood for days?

The paper that describes retatrutide's design links its long half-life to the molecule's construction. Retatrutide is a 39-amino-acid peptide on a GIP backbone with a C20 fatty diacid attached through a linker at Lys17, and that fatty-acid tail is a standard design for binding albumin, the carrier protein that makes up most of the protein in human blood (Coskun et al., Cell Metabolism, 2022). The paper also lists three engineered substitutions — Aib2, αMeL13, and Aib20 — as changes made to make the peptide harder for the body to break down.

Your albumin has been running a taxi service since long before anyone designed a peptide to hitch a ride. Fatty acids hop on, ride the circulation, and hop off where they are needed. A fatty-acid tail lets a peptide buy a ticket on the same service, and the paper presents that albumin binding as the design reason for the long half-life, a design rationale and not a measurement in people (Coskun et al., Cell Metabolism, 2022).

One honest limit sits underneath the story. The Coskun et al. (Cell Metabolism, 2022) paper checked on 14 October 2026 does not tabulate a human free fraction — the share of the compound travelling unbound — or a percentage bound, so this page does not supply one.

Is research-use retatrutide the same material the trials measured?

No. The human trial figures on this page were measured on the trial drug product, given to enrolled participants under clinical trial conditions (Coskun et al., Cell Metabolism, 2022; Urva et al., The Lancet, 2022). The one analytical study on this page, of four adults using retatrutide outside a trial, did not name its product source (Carneiro et al., Rapid Communications in Mass Spectrometry, 2026). Research-use reference material is a laboratory compound. Retatrutide's published trial pharmacokinetics therefore describe one specific investigational product studied in two Phase 1 trials. Research material is not a medicine, is not a substitute for one, and is not for human or animal use. The trial measurements describe what happened inside those trials; they say nothing about any material outside them.

What exists for laboratory work is reference material with paperwork. This site's retatrutide reference material listing is freeze-dried laboratory stock. Available reports cover historical samples; matching current certification is unverified. Reading that paperwork is its own skill — what a certificate records, what a third-party report proves, how a batch stays traceable — and the quality and verification hub walks through it. The TGA safety alert of 14 September 2026 reported that retatrutide is in ongoing human trials and is not approved by the TGA or a comparable international regulator.